Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells

EGFR/HER2 are frequently expressed in MPM tissues, however, no studies have shown the clinical benefit of using EGFR/HER2-targeting drugs in patients with malignant pleural mesothelioma (MPM). It was reported that the tyrosine kinase inhibitor (TKI) lapatinib enhanced trastuzumab-mediated antibody-d...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncol Rep
Main Authors: OKITA, RIKI, SHIMIZU, KATSUHIKO, NOJIMA, YUJI, YUKAWA, TAKURO, MAEDA, AI, SAISHO, SHINSUKE, NAKATA, MASAO
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2015
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4722889/
https://ncbi.nlm.nih.gov/pubmed/26503698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2015.4314
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki